Table 2. Laboratory methods to determine von Willebrand factor levels.
Measurement | Principle | Method | Advantage | Disadvantage | |
---|---|---|---|---|---|
vWF antigen (vWF:Ag) a | Quantity | Antibody captures protein | ELISA, LIA or flow cytometry | High availability in laboratories | Different cut-off values for different assays Not sensitive for low levels No differential sensitivity to variable molecular weight forms of vWF |
vWF propeptide (vWF:pp) a | Quantity | Antibody captures protein | ELISA | Sensitive parameter for vWF release | Different cut-off values for different assays Little commercial availability |
vWF ristocetin co-factor (vWF:RCo) a | Activity | Ristocetin induces platelet aggregation through GPIb–vWF interaction | Aggregometry, standard coagulation instruments, LIA or flow cytometry | High availability in laboratories Availability at the bedside with timely results |
High variation of coefficients Limited inter-laboratory reproducibility and standardization Poor sensitivity for low vWF levels |
vWF collagen binding (vWF:CB) | Activity | Collagen induces vWF binding | ELISA or flow cytometry | Sensitivity to high molecular weight vWF Sensitivity to low vWF levels Little variability |
Lack of comparative data |
vWF activity | Activity | Recombinant gain of function GPIb binds to vWF | LIA or ELISA | Easy performance and automation High assay accuracy and precision Detection of vWF at low levels |
Lack of comparative data |
Abbreviations: ELISA, enzyme-linked immunosorbant assay; GPIb, glycoprotein Ib; LIA, latex-particle immunoassay; vWF, von Willebrand factor.
Note: Key points for different assessment of von Willebrand factor.
Indicates tests used in stroke studies.